14.28
前日終値:
$14.12
開ける:
$14.5
24時間の取引高:
504.32K
Relative Volume:
1.63
時価総額:
$75.54M
収益:
$858.00K
当期純損益:
$-8.98M
株価収益率:
-69.35
EPS:
-0.2059
ネットキャッシュフロー:
$-29.81M
1週間 パフォーマンス:
+62.27%
1か月 パフォーマンス:
+69.40%
6か月 パフォーマンス:
+185.51%
1年 パフォーマンス:
+456.94%
Rallybio Corp Stock (RLYB) Company Profile
Compare RLYB vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
RLYB
Rallybio Corp
|
14.28 | 75.54M | 858.00K | -8.98M | -29.81M | -0.2059 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-09 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-05-15 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-02-07 | ダウングレード | Jefferies | Buy → Hold |
| 2023-04-17 | 開始されました | H.C. Wainwright | Buy |
| 2023-04-10 | 開始されました | Wedbush | Outperform |
| 2022-12-09 | 開始されました | JP Morgan | Overweight |
| 2022-02-22 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-08-23 | 開始されました | Cowen | Outperform |
| 2021-08-23 | 開始されました | Evercore ISI | Outperform |
| 2021-08-23 | 開始されました | Jefferies | Buy |
すべてを表示
Rallybio Corp (RLYB) 最新ニュース
[RW] Rallybio Corp SEC Filing - Stock Titan
Rallybio stock surges after receiving $50M termination fee By Investing.com - Investing.com Nigeria
Rallybio stock surges after receiving $50M termination fee - Investing.com
Rallybio merger scrapped; New Haven biotech to receive $50M breakup fee - Hartford Business Journal
Rallybio Corporation Files Form 8-K with SEC Detailing Waiver Agreement and Entity Information - Minichart
RLYB Stock Under Pressure As Merger Scrutiny Mounts - timothysykes.com
Rallybio Receives Termination Fee After Candid Deal Collapse - TipRanks
Rallybio, Candid and UCB Sign Waiver; $50 Million Fee Follows Merger Termination - TradingView
Rallybio CorpCandid terminates merger agreement with Rallybio on May 3, 2026SEC filing - marketscreener.com
Rallybio (RLYB) to receive $50,000,000 after Candid chooses UCB deal - Stock Titan
RLYB - Finviz
RLYB Stock Chart | RALLYBIO CORP (NASDAQ:RLYB) - ChartMill
[S-4/A] Rallybio Corp Amended Business Combination Registration | RLYB SEC FilingForm S-4/A - Stock Titan
Rallybio Corporation (RLYB) Sector Rotation | Rallybio Corporation notches 13.9% EPS beat on narrower lossCommunity Buy Signals - Xã Vĩnh Công
Is Rallybio Corporation (RLYB) stock a good opportunity (Institutional Demand) 2026-04-20Social Flow Trades - Cổng thông tin điện tử Tỉnh Sơn La
Johnson & Johnson Reduces Stake in Rallybio Corp: A Strategic Po - GuruFocus
Rallybio Corporation (RLYB) Stock: Price Structure (Hovering) 2026-04-16Trending Stock Ideas - Cổng thông tin điện tử Tỉnh Sơn La
Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders? - Eastern Progress
J&J (NYSE: JNJ) discloses 152,901‑share stake in Rallybio (RLYB) - Stock Titan
Will Rallybio Corporation (RLYB) Stock Outperform S&P 500 | Price at $8.24, Down 2.31%Top Breakouts - UBND thành phố Hải Phòng
RLYB Stock Quote - richtv.io
Rallybio Investors Confront Significant Dilution in Merger as $47.5M Valuation Marks Major Downturn from Earlier Projections - Bitget
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Terns Therapeutics, Inc. (Nasdaq – TERN), Whitestone REIT (NYSE – WSR), Rallybio Corporation (Nasdaq – RLYB), Day One Biopharmaceuticals, Inc. (Nasda - ChartMill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Are EWCZ, STEL, RLYB, CTRA Obtaining Fair Deals for their Shareholders? - The Malaysian Reserve
Setup Watch: Can Rallybio Corporation sustain earnings growth2026 Movers & Precise Entry and Exit Recommendations - baoquankhu1.vn
Is Rallybio Corporation (RLYB) Stock Cheap at Current Price | Price at $8.29, Down 1.60%Shared Momentum Picks - Cổng thông tin điện tử Tỉnh Sơn La
Is Rallybio Corporation (RLYB) Stock cyclical or stable | Price at $8.43, Up 0.36%Short Term Trading - Xã Thanh Hà
RLYB Technical Analysis & Stock Price Forecast - Intellectia AI
Rallybio CMO Departs Amid Pending Candid Therapeutics Merger - The Globe and Mail
AI Stocks: Is Rallybio Corporation stock trending bullishWeekly Trade Report & Daily Price Action Insights - baoquankhu1.vn
Rallybio chief medical officer departs as company announces leadership change By Investing.com - Investing.com South Africa
Rallybio chief medical officer departs as company announces leadership change - Investing.com Australia
Rallybio (RLYB) CMO Steven Ryder exits as Candid Therapeutics merger proceeds - Stock Titan
RLYB Should I Buy - Intellectia AI
RALLYBIO CORP (NASDAQ:RLYB) Passes Minervini Trend and High Growth Momentum Filters - ChartMill
Rallybio (NASDAQ:RLYB) Rating Increased to Hold at Wall Street Zen - Defense World
Rallybio to acquire Candid Therapeutics - MSN
Rallybio to acquire Candid Therapeutics in $505M merger deal - MSN
If You Invested $1,000 in Rallybio Corp (RLYB) - Stock Titan
Here's Why We're Watching Rallybio's (NASDAQ:RLYB) Cash Burn Situation - 富途牛牛
Halper Sadeh LLC is Investigating Whether RLYB, TALK, UNF are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Tiny biotech Rallybio stock surges as $500 million-backed merger fuels investor optimism - msn.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations - marketscreener.com
Rallybio CVRs Carry High Risk of Expiring Worthless Amid Uncertain Asset Monetization - TipRanks
Halper Sadeh LLC is Investigating Whether TALK, JTAI, RLYB are Obtaining Fair Deals for their Shareholders - The Norfolk Daily News
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—ALIS, TALK, JTAI, and RLYB - GlobeNewswire Inc.
Rallybio Corporation 2025 10-K: Clinical-Stage Rare Disease Biotech, Pipeline, Partnerships, and Regulatory Overview - Minichart
RLYB Surges on Revenue and Merger Hype Why the Stock Still Dropped - Bitget
Stock Recap: What hedge funds are buying Rallybio CorporationPortfolio Value Summary & Weekly High Conviction Ideas - baoquankhu1.vn
Rallybio (NASDAQ: RLYB) to become Candid after merger, $505.5M financing - Stock Titan
Rallybio Corp (RLYB) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):